CompletedPhase 1NCT00612989

Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM

Studying Gliosarcoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Duke University
Principal Investigator
David A. Reardon, MD, MD
Duke Health
Intervention
Temodar and O6-Benzylguanine(drug)
Enrollment
42 enrolled
Eligibility
18 years · All sexes
Timeline
20052008

Study locations (1)

Collaborators

Schering-Plough · Keryx / AOI Pharmaceuticals, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00612989 on ClinicalTrials.gov

Other trials for Gliosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Gliosarcoma

← Back to all trials